MX2017000409A - Forma cristalina novedosa de metansulfonato de 5-cloro-n-({(5s)-2-oxo-3-[4-(5,6-dihidro-4h-[1,2,4]triazin-1-il)f enil]-1,3-oxazolidin-5-il}metil)tiofen-2-carboxamida y composicion farmaceutica que contiene la misma. - Google Patents
Forma cristalina novedosa de metansulfonato de 5-cloro-n-({(5s)-2-oxo-3-[4-(5,6-dihidro-4h-[1,2,4]triazin-1-il)f enil]-1,3-oxazolidin-5-il}metil)tiofen-2-carboxamida y composicion farmaceutica que contiene la misma.Info
- Publication number
- MX2017000409A MX2017000409A MX2017000409A MX2017000409A MX2017000409A MX 2017000409 A MX2017000409 A MX 2017000409A MX 2017000409 A MX2017000409 A MX 2017000409A MX 2017000409 A MX2017000409 A MX 2017000409A MX 2017000409 A MX2017000409 A MX 2017000409A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline form
- novel crystalline
- oxazolidin
- triazin
- oxo
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 title 1
- YSNDMQDQQLSJMR-UQKRIMTDSA-N 5-chloro-n-[[(5s)-3-[4-(5,6-dihydro-2h-1,2,4-triazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2NC=NCC2)C1 YSNDMQDQQLSJMR-UQKRIMTDSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se relaciona con una forma cristalina novedosa de metansulfonato de 5-cloro-N-({(5S)-2-oxo-3-[4-(5,6-dih idro-4H-[1,2,4]triazin-1-il)fenil]-1,3-oxazolidin-5-il}metil)tiof en-2-carboxamida y una composición farmacéutica que contiene la misma. La forma cristalina novedosa de un compuesto de acuerdo con la presente invención muestra una estabilidad excelente incluso en ambientes de alta temperatura y humedad, y de este modo puede utilizarse de forma favorable para prevenir o tratar enfermedades tales como trombosis, infarto al miocardio, aterosclerosis, inflamación, aneurisma, angina de pecho, restenosis después de angioplastia, y tromboembolismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2014/006555 WO2016010178A1 (ko) | 2014-07-18 | 2014-07-18 | 5-클로로-ｎ-({(5ｓ)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017000409A true MX2017000409A (es) | 2017-05-01 |
Family
ID=55078662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000409A MX2017000409A (es) | 2014-07-18 | 2014-07-18 | Forma cristalina novedosa de metansulfonato de 5-cloro-n-({(5s)-2-oxo-3-[4-(5,6-dihidro-4h-[1,2,4]triazin-1-il)f enil]-1,3-oxazolidin-5-il}metil)tiofen-2-carboxamida y composicion farmaceutica que contiene la misma. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9988372B2 (es) |
| EP (1) | EP3170819B1 (es) |
| JP (1) | JP6450840B2 (es) |
| KR (1) | KR102100357B1 (es) |
| CN (2) | CN110407827B (es) |
| AU (1) | AU2014400894B2 (es) |
| BR (1) | BR112017000351B1 (es) |
| CA (1) | CA2955397C (es) |
| IL (2) | IL297649A (es) |
| MX (1) | MX2017000409A (es) |
| MY (1) | MY190477A (es) |
| PH (1) | PH12017500093A1 (es) |
| RU (1) | RU2663617C1 (es) |
| SG (1) | SG11201700066TA (es) |
| UA (1) | UA116182C2 (es) |
| WO (1) | WO2016010178A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019262286B2 (en) * | 2018-05-02 | 2022-08-11 | Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd | Thiophene derivative crystal form |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100898361B1 (ko) * | 2008-07-03 | 2009-05-20 | 주식회사 레고켐 바이오사이언스 | Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물 |
| KR101037052B1 (ko) | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | 5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체 |
-
2014
- 2014-07-18 KR KR1020167035812A patent/KR102100357B1/ko active IP Right Grant
- 2014-07-18 WO PCT/KR2014/006555 patent/WO2016010178A1/ko active Application Filing
- 2014-07-18 MX MX2017000409A patent/MX2017000409A/es active IP Right Grant
- 2014-07-18 SG SG11201700066TA patent/SG11201700066TA/en unknown
- 2014-07-18 RU RU2017105147A patent/RU2663617C1/ru active
- 2014-07-18 MY MYPI2016704816A patent/MY190477A/en unknown
- 2014-07-18 AU AU2014400894A patent/AU2014400894B2/en active Active
- 2014-07-18 CN CN201910687566.9A patent/CN110407827B/zh active Active
- 2014-07-18 CA CA2955397A patent/CA2955397C/en active Active
- 2014-07-18 US US15/325,521 patent/US9988372B2/en active Active
- 2014-07-18 BR BR112017000351-1A patent/BR112017000351B1/pt active IP Right Grant
- 2014-07-18 UA UAA201701494A patent/UA116182C2/uk unknown
- 2014-07-18 CN CN201480080661.8A patent/CN106661011B/zh active Active
- 2014-07-18 IL IL297649A patent/IL297649A/en unknown
- 2014-07-18 EP EP14897871.1A patent/EP3170819B1/en active Active
- 2014-07-18 JP JP2017523744A patent/JP6450840B2/ja active Active
-
2017
- 2017-01-13 PH PH12017500093A patent/PH12017500093A1/en unknown
- 2017-01-17 IL IL250168A patent/IL250168A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102100357B1 (ko) | 2020-04-13 |
| EP3170819B1 (en) | 2019-07-10 |
| NZ727829A (en) | 2021-01-29 |
| CN106661011B (zh) | 2020-01-10 |
| WO2016010178A1 (ko) | 2016-01-21 |
| KR20170023003A (ko) | 2017-03-02 |
| UA116182C2 (uk) | 2018-02-12 |
| AU2014400894A1 (en) | 2017-02-02 |
| MY190477A (en) | 2022-04-22 |
| PH12017500093A1 (en) | 2017-05-22 |
| AU2014400894B2 (en) | 2018-04-19 |
| US20170152251A1 (en) | 2017-06-01 |
| RU2663617C1 (ru) | 2018-08-07 |
| SG11201700066TA (en) | 2017-02-27 |
| IL297649A (en) | 2022-12-01 |
| US9988372B2 (en) | 2018-06-05 |
| EP3170819A4 (en) | 2018-05-16 |
| CN110407827A (zh) | 2019-11-05 |
| JP6450840B2 (ja) | 2019-01-09 |
| IL250168A0 (en) | 2017-03-30 |
| BR112017000351B1 (pt) | 2022-10-25 |
| CA2955397A1 (en) | 2016-01-21 |
| BR112017000351A2 (pt) | 2017-11-07 |
| CA2955397C (en) | 2019-01-08 |
| EP3170819A1 (en) | 2017-05-24 |
| JP2017521500A (ja) | 2017-08-03 |
| CN106661011A (zh) | 2017-05-10 |
| CN110407827B (zh) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PH12015500678A1 (en) | Crystalline forms of a factor xia inhibitor | |
| MX2021002259A (es) | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| WO2010017948A3 (en) | Pharmaceutical compositions of rivaroxaban with modified release properties | |
| PE20191142A1 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| CL2015000002A1 (es) | Forma de administracion farmaceutica que comprende 5-cloro-n-({(5s)-2-oxo -3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida; procedimiento de preparacion y uso en la profilaxis y/o tratamiento de trastornos tromboembolicos. | |
| HK1130252A1 (en) | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | |
| MD4557B1 (ro) | Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu | |
| UY33628A (es) | Nuevo monohidrato de derivados de aza-adamantano | |
| CY1122506T1 (el) | Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη | |
| PH12017500093A1 (en) | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same | |
| BR112018013364A2 (pt) | forma cristalina e composição farmacêutica | |
| IN2012MU03359A (es) | ||
| MX2016013875A (es) | Ingrediente activo (i) que contiene una composicion y metodo para prepararla. | |
| RU2012108794A (ru) | Керамическая масса для производства кирпича |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |